Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction

医学 射血分数 心力衰竭 射血分数保留的心力衰竭 心脏病学 内科学 缬沙坦 厄贝沙坦 重症监护医学 血压
作者
Kirsty McDowell,Toru Kondo,Atefeh Talebi,Ken Teh,Erasmus Bachus,Rudolf A. de Boer,Ross T. Campbell,Brian Claggett,Ashkay S. Desai,Kieran F. Docherty,Adrian F. Hernandez,Silvio E. Inzucchi,Mikhail Kosiborod,Carolyn S.P. Lam,Felipe A. Martínez,Joanne Simpson,Muthiah Vaduganathan,Pardeep S. Jhund,Scott D. Solomon,John J.V. McMurray
出处
期刊:JAMA Cardiology [American Medical Association]
卷期号:9 (5): 457-457 被引量:11
标识
DOI:10.1001/jamacardio.2024.0284
摘要

Importance Accurate risk prediction of morbidity and mortality in patients with heart failure with preserved ejection fraction (HFpEF) may help clinicians risk stratify and inform care decisions. Objective To develop and validate a novel prediction model for clinical outcomes in patients with HFpEF using routinely collected variables and to compare it with a biomarker-driven approach. Design, Setting, and Participants Data were used from the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial to derive the prediction model, and data from the Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction (PARAGON-HF) and the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-PRESERVE) trials were used to validate it. The outcomes were the composite of HF hospitalization (HFH) or cardiovascular death, cardiovascular death, and all-cause death. A total of 30 baseline candidate variables were selected in a stepwise fashion using multivariable analyses to create the models. Data were analyzed from January 2023 to June 2023. Exposures Models to estimate the 1-year and 2-year risk of cardiovascular death or hospitalization for heart failure, cardiovascular death, and all-cause death. Results Data from 6263 individuals in the DELIVER trial were used to derive the prediction model and data from 4796 individuals in the PARAGON-HF trial and 4128 individuals in the I-PRESERVE trial were used to validate it. The final prediction model for the composite outcome included 11 variables: N-terminal pro–brain natriuretic peptide (NT-proBNP) level, HFH within the past 6 months, creatinine level, diabetes, geographic region, HF duration, treatment with a sodium-glucose cotransporter 2 inhibitor, chronic obstructive pulmonary disease, transient ischemic attack/stroke, any previous HFH, and heart rate. This model showed good discrimination (C statistic at 1 year, 0.73; 95% CI, 0.71-0.75) in both validation cohorts (C statistic at 1 year, 0.71; 95% CI, 0.69-0.74 in PARAGON-HF and 0.75; 95% CI, 0.73-0.78 in I-PRESERVE) and calibration. The model showed similar discrimination to a biomarker-driven model including high-sensitivity cardiac troponin T and significantly better discrimination than the Meta-Analysis Global Group in Chronic (MAGGIC) risk score (C statistic at 1 year, 0.60; 95% CI, 0.58-0.63; delta C statistic, 0.13; 95% CI, 0.10-0.15; P < .001) and NT-proBNP level alone (C statistic at 1 year, 0.66; 95% CI, 0.64-0.68; delta C statistic, 0.07; 95% CI, 0.05-0.08; P < .001). Models derived for the prediction of all-cause and cardiovascular death also performed well. An online calculator was created to allow calculation of an individual’s risk. Conclusions and Relevance In this prognostic study, a robust prediction model for clinical outcomes in HFpEF was developed and validated using routinely collected variables. The model performed better than NT-proBNP level alone. The model may help clinicians to identify high-risk patients and guide treatment decisions in HFpEF.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
小王完成签到,获得积分10
刚刚
刚刚
完美世界应助研友_Z33zkZ采纳,获得10
刚刚
共享精神应助阿良采纳,获得10
1秒前
1秒前
chengzi完成签到,获得积分10
1秒前
kitten完成签到,获得积分10
1秒前
Asurary完成签到 ,获得积分10
2秒前
shuangcheng发布了新的文献求助10
3秒前
有点is完成签到,获得积分10
5秒前
5秒前
科研白完成签到,获得积分20
6秒前
Jzhu96发布了新的文献求助10
6秒前
嘻嘻完成签到,获得积分10
6秒前
6秒前
燕子发布了新的文献求助30
6秒前
科目三应助陈隆采纳,获得10
6秒前
852应助qzp98采纳,获得10
7秒前
星黛Lu发布了新的文献求助10
7秒前
欠虐宝宝完成签到 ,获得积分10
7秒前
7秒前
Cc发布了新的文献求助10
7秒前
文静的谷菱完成签到,获得积分10
8秒前
无花果应助emm采纳,获得10
8秒前
8秒前
Tina完成签到 ,获得积分10
8秒前
羞涩的文轩完成签到,获得积分10
8秒前
9秒前
丞123完成签到,获得积分10
9秒前
清风完成签到,获得积分10
9秒前
烟花应助鱼生采纳,获得10
9秒前
10秒前
phoenix完成签到,获得积分20
10秒前
10秒前
10秒前
郭guoguo完成签到,获得积分10
11秒前
12秒前
汪汪发布了新的文献求助10
12秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969060
求助须知:如何正确求助?哪些是违规求助? 3513962
关于积分的说明 11171223
捐赠科研通 3249302
什么是DOI,文献DOI怎么找? 1794772
邀请新用户注册赠送积分活动 875377
科研通“疑难数据库(出版商)”最低求助积分说明 804769